Hepatitis B

• 

  Subject Areas on Research

  • A cost-effectiveness analysis of hepatitis B vaccine in predialysis patients. 
  • A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels. 
  • A follow-up study of three hepatitis B virus markers in personnel from the Canadian Armed Forces. 
  • A novel variant marking HLA-DP expression levels predicts recovery from hepatitis B virus infection. 
  • A preS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly. 
  • A program for eradication of hepatitis B from Taiwan by a 10-year, four-dose vaccination program. 
  • Addressing cultural diversity: the hepatitis B clinical specialist perspective. 
  • Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. 
  • Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. 
  • Association between fulminant hepatic failure and a strain of GBV virus C. 
  • Association between hepatitis B virus and pancreatic cancer. 
  • Association of preexisting drug-resistance mutations and treatment failure in hepatitis B patients. 
  • Associations between HLA class I alleles and escape mutations in the hepatitis B virus core gene in New Zealand-resident Tongans. 
  • Carpal tunnel syndrome in hepatic disease. 
  • Clinical relevance of hepatitis B viral mutations. 
  • Clinical relevance of mutations in the precore genome of the hepatitis B virus. 
  • Comparative study of the immunogenicity and safety of two dosing schedules of hepatitis B vaccine in neonates. 
  • Delta hepatitis in North Carolina: learning from a patient. 
  • Development of fatal acute liver failure in HIV-HBV coinfected patients. 
  • Different kinetics of HBV and HCV during haemodialysis and absence of seronegative viral hepatitis in patients with end-stage renal disease. 
  • Don't share razors or toothbrushes. 
  • Donor origin of de novo hepatocellular carcinoma in hepatic allografts. 
  • Donor origin of de novo hepatocellular carcinoma in hepatic allografts. 
  • Downregulation of the AU-rich RNA-binding protein ZFP36 in chronic HBV patients: implications for anti-inflammatory therapy. 
  • Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. 
  • Efficacy of hepatitis B screening in a private obstetrical population. 
  • Elimination of Perinatal Hepatitis B: Providing the First Vaccine Dose Within 24 Hours of Birth. 
  • Epidemiology of hepatitis B in eastern Kenya. 
  • Exploring the causal machinery behind sex ratios at birth: does hepatitis B play a role? 
  • Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. 
  • Family physician acceptance of universal hepatitis B immunization of infants. 
  • Frequency and predictors of de novo hepatocellular carcinoma in patients awaiting orthotopic liver transplantation during the model for end-stage liver disease era. 
  • GB virus C/hepatitis G virus infection: a favorable prognostic factor in human immunodeficiency virus-infected patients? 
  • GBV-C/HGV is not the major cause of autoimmune hepatitis. 
  • HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration. 
  • HCV core antigen testing in HIV- and HBV-coinfected patients, and in HCV-infected patients on hemodialysis. 
  • Hepatic failure in adult Niemann-Pick disease. 
  • Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. 
  • Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. 
  • Hepatitis B and C viruses in infants and young children. 
  • Hepatitis B and C: prevalence and risk factors associated with seropositivity among children in Karachi, Pakistan. 
  • Hepatitis B antigen in saliva, urine, and stool. 
  • Hepatitis B core antibody positive donors as a safe and effective therapeutic option to increase available organs for lung transplantation. 
  • Hepatitis B core antibody-positive donors in cardiac transplantation: a single-center experience. 
  • Hepatitis B in a medical center. 
  • Hepatitis B testing and diagnosis experiences of patients and primary care professionals in Australia. 
  • Hepatitis B vaccination and booster in predialysis patients: a 4-year analysis. 
  • Hepatitis B vaccination in HIV-infected youth: a randomized trial of three regimens. 
  • Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response. 
  • Hepatitis B virus reactivation or reinfection in a FEM-PrEP participant: a case report. 
  • Hepatitis B virus vaccine. An analysis of its potential use in medical workers. 
  • Hepatitis B virus vaccine: cost effects and insurance coverage. 
  • Hepatocytic expression of human sodium-taurocholate cotransporting polypeptide enables hepatitis B virus infection of macaques. 
  • Ignoring the obvious missing piece of chronic kidney disease in HIV: cigarette smoking. 
  • Impaired generation of hepatitis B virus-specific memory B cells in HIV infected individuals following vaccination. 
  • Importance of sampling frame in physician surveys. 
  • Infectious complications in extended criteria heart transplantation. 
  • Isolated abducens nerve palsy following neonatal hepatitis B vaccination. 
  • Isolated anti-HBV core phenotype in anti-HCV-positive patients is associated with hepatitis C virus replication. 
  • Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. 
  • Lamivudine-resistant hepatitis B virus infection post-liver transplantation from a hepatitis B core antibody donor. 
  • Large artery vasculitis following recombinant hepatitis B vaccination: 2 cases. 
  • Liver transplantation in HIV/hepatitis co-infection. 
  • Longer survival of liver transplant recipients with hepatitis virus coinfections. 
  • Low incidence of acute rejection in hepatitis B virus positive liver transplant recipients and the impact of hepatitis B immunoglobulin. 
  • Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat? 
  • Maternal immunisation and neonatal infection of hepatitis A or B virus - Authors' reply. 
  • Mortality from sexually transmitted diseases in reproductive-aged women: United States, 1999-2010. 
  • Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. 
  • Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. 
  • Non-Hodgkin's lymphomas, version 1.2013. 
  • Non-genetic risk factors and predicting efficacy for docetaxel--drug-induced liver injury among metastatic breast cancer patients. 
  • Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfected patients with incomplete hepatitis B virus viral suppression. 
  • Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. 
  • Pegylated interferon and ribavirin for the recurrence of chronic hepatitis C genotype 1 in transplant patients. 
  • Persistence of antibody in healthcare workers vaccinated against hepatitis B. 
  • Persistence of occult hepatitis B after removal of the hepatitis B virus-infected liver. 
  • Plasma therapy in immunodeficiency diseases. 
  • Posttransplant B, non-A non-B, and cytomegalovirus hepatitis increase the risk of developing chronic rejection after liver transplantation. 
  • Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug. 
  • Pregnancy outcomes associated with viral hepatitis. 
  • Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. 
  • Prevalence of hepatitis B among pregnant women and its impact on pregnancy and newborn complications at a tertiary hospital in the eastern part of Germany. 
  • Prevalence, aetiology and associated co-morbidities of elevated aminotransferases in a german cohort of orthopaedic surgery patients. 
  • Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only. 
  • Prognostic implications of lactate, bilirubin, and etiology in German patients with acute liver failure. 
  • Racial differences in hepatitis B and hepatitis C and associated risk behaviors in veterans with severe mental illness. 
  • Randomized trial to determine safety and immunogenicity of two strategies for hepatitis B vaccination in healthy urban adolescents in the United States. 
  • Reactions of pediatricians to a new Centers for Disease Control recommendation for universal immunization of infants with hepatitis B vaccine. 
  • Reactivated fulminant hepatitis B virus replication after bone marrow transplantation: clinical course and possible treatment with ganciclovir. 
  • Relationship between human leukocyte antigen determinants and courses of hepatitis B virus infection in Caucasian patients with end-stage renal disease. 
  • Removing a major barrier to universal hepatitis B immunization in infants. 
  • Resection of hepatocellular carcinoma without cirrhosis. 
  • Response to hepatitis B immunization in children with hemophilia: relationship to infection with human immunodeficiency virus type 1. 
  • Response to interferon alpha therapy is influenced by the iron content of the liver. 
  • Results of a pilot test of a brief computer-assisted tailored HIV prevention intervention for use with a range of demographic and risk groups. 
  • Review of the use of hepatitis B core antibody-positive kidney donors. 
  • Risk factors for HIV, hepatitis B, and hepatitis C among persons with severe mental illness. 
  • Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. 
  • Risks and benefits of nucleosides before and after liver transplantation. 
  • SENP3-mediated host defense response contains HBV replication and restores protein synthesis. 
  • Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. 
  • Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. 
  • Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. 
  • Serological evidence of cross infection in a dialysis unit hepatitis-B epidemic. 
  • Seroprevalence of hepatitis A, B, and C in a United States military recruit population. 
  • Short and Long-Term Postoperative Complications Following Total Joint Arthroplasty in Patients With Human Immunodeficiency Virus, Hepatitis B, or Hepatitis C. 
  • Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. 
  • Successful hepatitis B reinfection prophylaxis with lamivudine and hepatitis B immune globulin in patients with positive HBV-DNA at time of liver transplantation. 
  • Successful orthotopic liver transplantation. 
  • Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. 
  • Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. 
  • Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan. 
  • TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. 
  • The "PHS Increased Risk" Label Is Associated With Nonutilization of Hundreds of Organs per Year. 
  • The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. 
  • The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. 
  • The five-site health and risk study of blood-borne infections among persons with severe mental illness. 
  • The increasing impact of human immunodeficiency virus infections, sexually transmitted diseases, and viral hepatitis in Durham County, North Carolina: a call for coordinated and integrated services. 
  • The long-term course of hepatitis C after kidney transplantation. 
  • The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study. 
  • The risk of hepatitis B transmission from health care workers to patients in a hospital setting--a prospective study. 
  • Therapy of acute and fulminant hepatitis B. 
  • Transmissible agents and the surgeon. 
  • Transmission of hepatitis B by a human bite: an occupational hazard. 
  • Transmission of hepatitis B virus from an orthopedic surgeon with a high viral load. 
  • Treatment of hepatitis B in special patient groups: hemodialysis, heart and renal transplant, fulminant hepatitis, hepatitis B virus reactivation. 
  • Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial. 
  • Universal hepatitis B immunization of infants: reactions of pediatricians and family physicians over time. 
  • Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease. 
  • Vaccinations for pregnant women. 
  • Viral infections in the acquired immunodeficiency syndrome. 
  • Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. 
  • Virological and clinical characteristics of delta hepatitis in Central Europe. 
  • [Acute hepatitis B: is antiviral therapy indicated? Two case reports]. 
  • [Characteristics of hepatitis and influenza antivirals: update 2009]. 
  • [HIV infection in immigrants in Spain: Epidemiological characteristics and clinical presentation in the CoRIS Cohort (2004-2006)]. 
  • [Prevalence of hepatitis B in pregnancy and selective screening]. 
  • [Virus associated glomerulonephritis]. 
• 

  Keywords of People

  • Clements III, Dennis Alfred, Professor Emeritus of Pediatrics, Pediatrics, Primary Care Pediatrics
  • Cunningham, Coleen Kathryn, Professor of Pediatrics, Pathology
  • Milano, Carmelo Alessio, Professor of Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • Thomann, Wayne R., Assistant Professor of Family Medicine and Community Health, Family Medicine & Community Health,Occupational & Environmental Medicine
  • Wu, Li-Tzy, Professor in Psychiatry and Behavioral Sciences, Medicine, General Internal Medicine